Paper Details

  1. Home
  2. Paper Details

Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma.

Author: Al HadidiSamer, KambleRammurti, Miller-ChismCourtney Nicole, MimsMartha

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

An integrated safety analysis of 1798 daratumumab-treated and 1797 comparator-treated patients with multiple myeloma (MM) found a favorable benefit/risk profile for daratumumab. Discontinuation for any reason occurred less often with daratumumab, and deaths owing to adverse events (AEs) were similar in both groups. The most common grade 3/4 AEs with daratumumab were neutropenia, lymphopenia, diarrhea, fatigue, dyspnea, pneumonia, and hypertension.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Multiple studies have demonstrated the efficacy and safety of daratumumab for relapsed/refractory multiple myeloma (MM) and primary treatment for transplant-eligible and -ineligible patients. MATERIALS AND METHODS: We conducted an integrated safety analysis to characterize the frequency...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clml.2020.04.004

データ提供：米国国立医学図書館（NLM）

Daratumumab: A Powerful Weapon Against Multiple Myeloma

Multiple myeloma, a type of blood cancer, is a challenging disease to treat, much like navigating a treacherous sandstorm in the desert. This study investigates the safety and efficacy of daratumumab, a new treatment for multiple myeloma, a bit like discovering a powerful weapon against a dreaded enemy. The researchers analyzed data from five clinical trials to assess the drug's safety profile.

A Promising Treatment with Considerations

The study showed that daratumumab was generally well-tolerated and effective in treating multiple myeloma. This is encouraging news, as it offers a new hope for patients battling this difficult disease. However, the study also highlighted potential side effects, such as neutropenia, lymphopenia, diarrhea, fatigue, and pneumonia. This is like finding a powerful sword that can cut through enemies but can also be dangerous if wielded carelessly. The study also found that the majority of infusion-related reactions, which are side effects that occur during the infusion of the drug, occurred after the first infusion.

Finding the Right Balance

This study provides a balanced perspective on daratumumab, highlighting its potential benefits as well as its potential risks. It is a reminder that every treatment comes with tradeoffs, and that careful monitoring and management are crucial for optimizing patient outcomes. Just as a camel caravan must carefully choose its route to minimize the risk of encountering dangers, healthcare providers must carefully weigh the risks and benefits of daratumumab when treating patients with multiple myeloma.

Dr.Camel's Conclusion

This research emphasizes the importance of thorough evaluation of new drugs, considering both their efficacy and their safety. It is a reminder that the pursuit of new treatments for challenging diseases is a delicate balancing act, requiring both optimism and a dose of realism.

Date :
  1. Date Completed 2021-09-07
  2. Date Revised 2021-09-07
Further Info :

Pubmed ID

32409106

DOI: Digital Object Identifier

10.1016/j.clml.2020.04.004

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.